HALO
Halozyme Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.57B
P/E Ratio
24.95
EPS
$2.56
Beta
1.03
52W High
$82.22
52W Low
$47.50
50-Day MA
$66.84
200-Day MA
$68.38
Dividend Yield
—
Profit Margin
22.70%
Forward P/E
4.75
PEG Ratio
-2.50
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.40B |
| Gross Profit (TTM) | $1.09B |
| EBITDA | $897.84M |
| Operating Margin | 56.30% |
| Return on Equity | 153.60% |
| Return on Assets | 22.20% |
| Revenue/Share (TTM) | $11.65 |
| Book Value | $0.41 |
| Price-to-Book | 156.52 |
| Price-to-Sales (TTM) | 5.42 |
| EV/Revenue | 6.9 |
| EV/EBITDA | 16.82 |
| Quarterly Earnings Growth (YoY) | 36.20% |
| Quarterly Revenue Growth (YoY) | 51.60% |
| Shares Outstanding | $118.47M |
| Float | $116.71M |
| % Insiders | 1.08% |
| % Institutions | 107.94% |
Historical Volatility
HV 10-Day
29.84%
HV 20-Day
29.29%
HV 30-Day
29.45%
HV 60-Day
34.94%
HV Rank
48.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($85.22 target)
2
Strong Buy4
Buy2
Hold1
SellData last updated: 4/29/2026